

Peri-implant maintenance of immediate function implants: A randomized controlled clinical trial comparing hyaluronic acid and chlorhexidine.

AUTHORS:

Miguel de Araújo Nobre, RDH, Private practice, Department of Oral Hygiene;
Department of Clinical Research, Clínica Malo, Lisbon, Portugal;

Nuno Cintra, DDS, MSc, Private practice, Department of Oral Surgery, Clínica Maló,
Lisbon, Portugal;

Paulo Maló, DDS, Private practice, Department of Implantology and Prosthodontics,
Clínica Maló, Lisbon, Portugal.

RUNNING TITLE: Evaluate an implant maintenance protocol

CORRESPONDENCE TO: Miguel de Araújo Nobre, RDH, Address: Clínica Malo,

Avenida Dos Combatentes, 43, 9C, Edifício Green Park, 1600-042 Lisbon, Portugal,

Phone: +351 21 722 81 00, fax: +351 21 726 6965, e-mail: mignobre@gmail.com;

mnobre@clinicamalo.pt

ABSTRACT

Introduction: In implants, maintenance assumes an important role. The role of chlorhexidine is well known in maintenance, while only limited evidence exists about the practical use of hyaluronic acid. The objective of this study was to compare the healing of immediate function implants, inside a maintenance protocol using hyaluronic acid and chlorhexidine gels.

Study population and methodology: Thirty complete edentulous patients, with 4 immediate function Brånemark System implants placed in the mandible (total of 120 implants), were included in 2 groups (hyaluronic acid and chlorhexidine) using only these 2 chemicals in their daily implant self-care. Both groups were followed for 6 months, with clinical observations on the 10th day, 2 months, 4 months and 6 months post-surgically.

Results: No implant losses were registered at 6 months in both groups. Hyaluronic acid and chlorhexidine produced good results on maintenance of complete rehabilitations in the edentulous mandible with immediate function implants. Statistically significant differences were found in favour of the hyaluronic acid group in the Modified bleeding index on the 2nd observation ($p=0.003$). The difference was located in the the axial implants placed in the 5th sextant ($p=0.05$). Correlation coefficient between plaque and bleeding index revealed a potential better result for chlorhexidine at 6 months.

Conclusion: The findings point out the importance of a maintenance protocol in immediate function implants. Both chemicals are valid tools for implant maintenance, with a proper timing of administration (hyaluronic acid in the first 2 months; chlorhexidine between 2-6 months).

KEY WORDS: maintenance, oral implants, immediate function; hyaluronic acid; chlorhexidine, gel, tilted implants; axial implants, oral hygiene

INTRODUCTION

In recent years more studies have been dealing with the concept of immediate function in implantology, which consists in the placement of the implant, abutment and crown on the same surgical step (1).

The maintenance phase of prosthetic rehabilitations with immediate function implants, assumes a role as important as the surgical phase, influencing the implants success rate (2, 3). The patient's oral hygiene has a significative impact on bone stability around osseointegrated implants, and even in complete edentulous patients, a bad oral hygiene relates to an increased bone loss (4). Moreover, the best way of treating peri-implant pathologies is still to prevent it (5, 6).

Hyaluronic acid (HA) is described as a natural organic substance, with physiological therapy activity, main component of the extracellular matrix of many tissues such as skin, synovial joints and periodontal tissues (7), with multi-functional role in healing of cronical lesions, including those that are observed in periodontal disease (8). Also in non-surgical treatment of periodontal disease, where the administration of high molecular weight HA proved to be effective in inducing tissue repair and healing in patients with inflammatory gingivitis and surgical wounds (7, 9, 10, 11).

Still, references in the literature for long-term use of hyaluronic acid in maintenance are sparse.

Chlorhexidine (CHX) represents the most efficient molecule of all antiseptic used in the oral cavity (12,13), with its efficacy attributed to the bactericide effect (the lethal effect of chlorhexidine is related to extensive intra-cellular damage inflicted in bacteria), to the bacteriostatic effect (which becomes lethal with the increasing concentration, causing

precipitation or coagulation of bacteria cytoplasm), and to its substantivity in the oral cavity, being its antimicrobial effect attributed to its di-cationic structure (14,15,16).

The aim of this randomized clinical controlled trial, was to compare the healing of the peri-implant complex in 2 groups of patients: 1- using 0.2% HA gel for daily implant self-care; 2- using 0.2% CHX gel for daily implant self-care; testing the hypothesis that healing of peri-implant mucosa would follow the same distribution for the implants in HA and CHX groups, tested by comparing the clinical and radiological evaluation parameters.

Study population and methodology

This study was performed between January 2004 and December 2004 at a private practice, Clinica Maló in Lisbon, Portugal. The implants were placed and monitored by the same team.

The participants for this study were selected according to an inclusion criterion that consisted in patients submitted to a complete fixed prosthetic rehabilitation of the mandible with 4 immediate function implants: two anterior implants placed in axial position and two posterior implants tilted up to 40° distally, placed immediately in front of the mental foramens bilaterally (17). The implants consisted in Brånemark System™ Mk III Ti-Unite Ø 4X15mm (Nobel Biocare AB™). The surgical, prosthetic and post-surgical protocols (medication) were followed according to the author's recommendations.

Other inclusion criteria consisted in the participants having to be present in the maintenance controls; and all participants needed to be followed for 6 months.

Smokers, patients with systemic and/or local contra-indications; patients with bruxism; patients with generalized oral inflammation/ infection; diagnosis of an oral pathology that would be impeditive of continuing the study; the use of antibiotics beyond the first 10 days after surgery; and patients that did not complete the follow-up were excluded from this study.

Clinical evaluation parameters:

The clinical evaluation parameters performed for monitoring of healing consisted in: Modified plaque index (mPLI) (18); Modified bleeding index (mBI) (18); Probing pocket depth (PPD) in millimetres (19), assessed with a calibrated Kerr-Hawe® Perio-probe; Suppuration (Sup), observed after applying finger pressure to the peri-implant complex and registered as present or absent (20); Clinical implant mobility (Mob) accessed manually and registered as present or absent (19).

Radiological evaluation parameters

The radiological evaluation consisted in observations of periapical x-rays (x-ray) registering radiolucent areas around the implant as present or absent (19). The radiographs were taken at the 3rd observation, around 4 months, using a Trophy® x-ray; Kodak® pellicles and anterior/posterior film holders Superbite Hawe-Neos®, to secure an orthognatic position of the film.

Methodology for data collection

The patients were randomly assigned to each group. An organized index was built to collect all clinical and radiological parameters from patients. Table 1, illustrates the clinical sequence of the study. One day before surgery (Day-1), the study design was explained to patients and a written consent was requested. On the day of surgery, an oral

hygiene clinical appointment was performed on the patient, where besides the prophylactic procedures, oral hygiene instructions were given about the tooth brush (7/100®, Pierre-Fabre Dermo-Cosmétique, Lda, Portugal) and the gel used: 0.2% HA gel (Gengigel®, Ricerfarma rfa, Italy) for group 1, or 0.2% CHX gel (Elugel®, Pierre-Fabre Dermo-Cosmétique Lda, Portugal) for group 2. The patients were instructed to abdicate from using any other mechanical or chemical means of removing dental plaque besides the toothbrush and the HA or CHX gel.

At day 10 post-surgically, the prosthesis was removed, followed by suture removal and initial clinical indexes assessment. The patients were re-instructed about their self care, and another tooth brush was delivered (15/100®, Pierre-Fabre Dermo-Cosmétique, Lda) to substitute the one delivered at day -1. At 2, 4 and 6 months post-surgically, the clinical sequence was repeated, adding a peri-apical x-ray at 4 months for monitoring radiolucent areas around the implant. In between the maintenance appointments, the patients maintained their rehabilitation using just the toothbrush and either the HA or CHX gels.

Statistical analysis

Descriptive and inferential statistics for all clinical and radiological parameters were performed, to evaluate the results of the two therapies, using a significance level of 5%. Two statistical approaches were used. The first, on patient level, analysed 30 participants, divided in two groups of 15. The second approach (at implant level), analysed the mBI at 2 months, to compare data from the position of the implant, comparing each of the four implants within the two groups, with a total of 8 groups with 15 implants.

Spearman correlation coefficients were used to establish the degree of association between dental plaque (mPII) and peri-implant mucosal bleeding (mBI).

RESULTS

The sample was represented by 30 individuals, of both genders with ages between 44 and 80 years (mean 58.6 +/- 9.51). Age did not differ between the 2 groups ($p=0.346 > 0.05$) (t-test).

A total of 120 implants were placed in these 30 patients, 4 on each patient, and all patients were followed for the proposed time in this study.

Clinical evaluation parameters on patient level

(A) mPII

The general level of mPII was average, with a median of 1.5 and 1 in the first three observations, and in the 4th observation respectively. The observed means for the 4 observations were 1.4 (+/-0.9 in the 1st observation); 1.3 (+/-0.8 in the 2nd observation); 1.5 (+/-0.6 in the 3rd observation); 1.2 (+/- 0.9 in the 4th observation).

The difference in mPII between the 2 groups was found not to be statistically significant in any of the 4 observations ($p>0.05$).

(B) mBI

On a general level, the mBI values were very low, with a median of 0 and 1 at the first three observations and 4th observation respectively. The observed means for the 4 observations were 0.35 (+/- 0.53 in the 1st observation); 0.18 (+/- 0.36 in the 2nd observation); 0.13 (+/- 0.26 in the 3rd observation); 0.97 (+/- 0.67 in the 4th observation).

There were no statistical significant differences in the mBI of the 2 groups in the 1st, 3rd and 4th observations. A statistical significant difference was found between the 2 groups, in the mBI of the 2nd observation in favour of the hyaluronic acid gel ($p=0.003 < 0.05$).

(C) PPD

The mean PPD was 2mm for both groups. The difference was found not statistically significant between the 2 groups at any observation ($p>0.05$).

(D) Mob

No differences were found between the two groups, as no implant was found mobile when clinically tested.

(E) Sup

No differences were found between the 2 groups, as no implant presented suppuration when clinically tested.

Radiological evaluation parameter

No differences were found between the 2 groups, as no implant presented radiolucency around it when radiologically tested.

Clinical evaluation parameters on implant level

This approach was applied to the mBI on the 2nd observation period, to assess the nature of the difference between the 2 groups (site related or a sum of small differences).

For the tilted implants localized in the posterior region (bilateral 3rd and 4th quadrant), no statistical significant difference was found between the 2 groups.

For the axial implants localized anteriorly in the 3rd and 4th quadrant, a statistical significant difference was found between the 2 groups, in favour of the HA group ($p=0.050$).

Correlation coefficient between MPII and MBI

The Spearman correlation coefficient was analyzed for the 2 groups in the 3 observations between mPII and mBI (Figure 1).

Regarding the HA group, coefficient correlation between mPII and mBI for the 1st observation was a negative weak not statistically significant ($r = -.328$; $p = 0.232$); at the 3rd observation it was observed a positive yet not statistically significant correlation ($r = .481$; $p = 0.070$); while at the 4th observation it was observed a positive strong statistically significant correlation ($r = .716$; $p = 0.003$). The correlation for the 2nd observation did not make sense because the variance of that sample was 0.

Regarding the CHX group, coefficient correlation was characterized by a positive weak and not statistically significant in the 1st observation ($r = .191$; $p = 0.495$) and 2nd observation, ($r = .024$; $p = 0.932$); a negative weak not statistically significant correlation in the 3rd observation, ($r = -.379$; $p = 0.164$); and a negative strong statistically significant correlation in the 4th observation ($r = -.625$; $p = 0.013$).

DISCUSSION

In a general way, HA and CHX produced very positive results in the maintenance of complete edentulous mandible rehabilitations with fixed prostheses supported by immediate function implants.

Maintenance is key if one aims at implant success, having been observed in this study that having a maintenance strategy for implants, accounts for good clinical outcomes up to 6 months post-surgically. These results can be supported in the literature, where oral hygiene's significant impact on bone stability around osseointegrated implants was verified (2,3); moreover in complete edentulous patients rehabilitated prosthetically, where an insufficient oral hygiene related to a higher bone loss (4).

The gel as mean of chemical administration has proved valid (21), as its specific action together with mechanical stimulation of the tissues when used as a main therapy in conjunction with brushing (22,23,24), allows achieving better results than with a mouthwash (25).

In this study, the main comparison between the peri-implant complexes of the 2 groups was the relation between the mPII and the mBI, in which is found the key to maintenance, as both plaque and bleeding indexes are reliable parameters for evaluating the patient's home care and the health of the peri-implant mucosa, respectively (19). During the course of the study, the plaque indexes never differed significantly between both groups. This implies that oral hygiene practice did not differ between the participants, therefore simplifying the analysis of the bleeding index, meaning that a higher or lower result in the two groups would not have been directly related to the dental hygiene abilities but to the chemicals in test.

The mPII level was generally average, meaning that dental plaque was always present around the implants, being possible to be observed by the naked eye. This presence of dental plaque means that the patients didn't achieve high levels of dental hygiene self-care, fact that could be explained by the lack of compliance or ability to perform self care (26), by difficult prosthetic design not making it simple for the patient to maintain it (27), or by the fact that the patients only maintenance tool was the tooth brush, without other supportive mechanical means of dental plaque removal.

The presence of dental plaque, represents an etiological factor for the development of peri-implant disease (28).

In our study, despite the plaque indexes were average (establishing good conditions for the development of peri-implant pathology), the bleeding index was extremely low (mean: 1st observation= 0.350; 2nd observation= 0.183; 3rd observation= 0.133; 4th

observation= 0.967), indicating excellent peri-implant health and suggesting that the pathological effect of dental plaque was inhibited.

These results were also observed in the literature, as several studies observed an improvement in gingival patterns for HA (10) as well as for CHX therapy, but the later, along with a constant dental plaque index level, or an increase of supra-gingival calculus (29,30).

For HA, the possible mechanisms for these results include the bacteriostatic effect patterns (observed *in vitro*), on microorganisms such as *Porphyromonas gingivalis*, *Actinobacillus actinomycetemcomitans*, *Staphylococcus aureus*, leading to a decrease in the risk of post-surgical infection and promoting a more predictable regeneration (31).

For CHX, the possible explanation mechanisms for the reduction of bleeding indexes include a possible reduction of pathogenic bacteria in dental plaque and/or a reduction of plaque metabolism (29); its the bactericide and substantivity effect (32); its bacteriostatic effect, by reducing the amount of active cultures of gram + microorganisms (*Staphylococcus aureus*) and gram - (*Porphyromona/Prevotella spp e Fusobacterium spp*) after 3 months (33); by its particular effect on the neutralization of pathogenic agents such as *Staphylococcus aureus*, *Porphyromona gingivalis e Prevotella intermedia* (observed *in vitro*) (34); or by a decrease on the oedema, vasodilatation and presence of pro-inflammatory citoquine interleuquine-8 (based on a inflammation model) (35).

In our study however, despite having proved that the use of these chemicals induced an inhibition of the dental plaque pathological effect over peri-implant tissues (due to the presence of dental plaque and the extremely low bleeding index), it was not possible to determine with assurance this mechanism of inhibition, and because no microbiological tests were performed, this question remains open.

The statistical significant difference favourable to the HA on the modified bleeding index in the 2nd observation (around 2 months post-surgically), rejects the hypothesis that healing of the peri-implant mucosa follows the same distribution for the implants in HA and CHX groups. Regarding the implant level analysis, a statistically significant difference was found in favour of HA localized on the anterior implants (the 5th sextant axial implants). These differences were observed at a time interval where the soft tissue finalized its healing, and therefore, the HA acted as a healing agent. This healing effect is related to the modulation and acceleration of the host response by the HA, as a consequence of its numerous biochemical and biophysical properties, its non-toxic effect, and its biocompatibility (36).

Complementing the results, there is the correlation between mPII and mBI (Figure 1). In this evaluation, we can observe a pattern in the association between mPII and mBI, where in HA came from a negative correlation in the 1st observations to a positive correlation in the 4th observation ($r = .716$; $p = 0.003$); while an opposite correlation occurred for CHX, coming from a positive correlation in the 1st observation to a negative correlation on the 4th observation ($r = -.625$; $p = 0.013$), demonstrating a tendency to potentiate the CHX effect in detrimental to HA on a long term. These results find parallel in the literature, where significant positive changes in gingival health are reported, as for the increasing of supra-gingival calculus, in patients submitted to a CHX therapy for 6 months (22,37).

Taking into consideration these results, the authors suggest an optimal period for HA administration in the first 2 months post-surgically, due to this time frame representing a healing period; while CHX administration should be used for the remaining period (between 2 and 6 months post-surgically), since this time frame represents an exclusively maintenance period.

More and larger randomized controlled trials are needed so to explore the effect of these agents over implants on both the clinical and microbiological levels, generating efficient maintenance protocols, with the objective of increasing the success in implantology.

Uncorrected version

BIBLIOGRAPHIC REFERENCES

1. Maló P, Rangert B, Dvarsater L. Immediate Function of Brånemark Implants in the Esthetic Zone - A retrospective Clinical Study with 6 Months to 4 Years of Follow-up. *Clin Impl Dent Relat Res* 2000; 2(3): 138-146.
2. Bauman GR, Mills M, Rapley JW, Hallmon WW. Implant maintenance: debridement and peri-implant home care. *Compendium* 1991; 12(9): 644, 646, 648 passim.
3. Hillenburg KL, Kosinski TF, Mentag PJ. Control of peri-implant inflammation. *Practical Periodontics and Aesthetical Dentistry* 1991; 3(8): 11-16.
4. Quirynen M, DeSoete M, VanStreenberghe D. Infectious risks for oral implants: a review of the literature. *Clin Oral Impl Res* 2002; 13: 1-19.
5. Jovanovic S. Peri-Implant Tissue Response to Pathological Insults. *Adv Dent Res* 1999; 13: 82-86.
6. Clarizio LF. Peri-implant infections. *Atlas of Oral Maxillofac Surg Clin North Am* 2000; 8(1): 35-54.
7. Rabasseda X. The role of hyaluronic acid in the management of periodontal disease. *Drugs of today* 2000; 36: 1-20.

8. Mesa FL, Aneiros J, Cabrera A et al. Antiproliferative effect of topical hyaluronic acid gel. Study in gingival biopsies of patients with periodontal disease. *Histol Histopathol* 2002; 17(3): 747-753.
9. Vangelisti R, Pagnacco O, Erra C. Hyaluronic acid in the topical treatment of gingival inflammations: preliminary clinical trial. *Translation of Attualità Terapeutica Internazionale* 1997; 3: 1-7.
10. Jentsch H, Pomowski R, Kundt G, Gocke R. Treatment of gingivitis with hyaluronan. *Journal of Clinical Periodontology* 2003; 30: 159-164.
11. Pagnacco O, Vangelisti R, Erra C, Poma A. Double-blind clinical trial vs. Placebo of a new sodium-hyaluronate-based gingival gel. *Translation of Attualità Terapeutica Internazionale* 1997; 4: 1-12.
12. Kamagate A, Kone D, Coulibaly NT, Brou E, Sixou M. In vitro study of chlorhexidine resistance in subgingival bacteria. *Odontostomatol Trop* 2002; 25 (97): 5-10.
13. Eren K, Ozmeriço N, Sardas S. Monitoring of buccal epithelial cells by alkaline comet assay (single cell gel electrophoresis technique) in cytogenetic evaluation of chlorhexidine. *Clin Oral Inv* 2002; 6: 150-154.
14. Hennessey TD. Antibacterial properties of hibitane. *J Perio Res* 1977; 4: 36-48.

15. Salas Campos L, Gomez FO, Villar MH, Martin RB. Antiseptic agents: chlorhexidine. *Rev Enferm* 2000; 23 (9): 637-640.
16. Moshrefi A. Chlorhexidine. *Journal West Soc Periodontol* 2002; 50(1): 5-9.
17. Maló P, Rangert B, Nobre M. "All-on-Four" Immediate-Function Concept with Branemark System Implantes for Completely Edentulous Mandibles - A Retrospective Study. *Clin Impl Dent Relat Res* 2003; 5 (suppl 1): 2-10.
18. Mombelli A, Van Oosten MAC, Shurch E, Lang NP. The microbiota associated with successful or failing osseointegrated titanium implants. *Oral Microbiol Imm* 1987; 2: 145-151.
19. Buser D, Weber HP, Lang NP. Tissue integration of non-submerged implants 1-year results of a prospective study with 100 ITI hollow-cylinder and hollow-screw implants. *Clin Oral Impl Res* 1990; 1: 33-40.
20. Maló P. Clinical applications of immediate function implants on completely edentulous maxilla with full arch fixed bridge. In: Chiappasco M, eds. *Osteointegrazione e carico immediate. Fondamenti biologici e applicazioni cliniche*. Milano, Italia: Masson, Spa, 2002: 60-102.
21. John V, Phillips G. Locally delivered antimicrobials in periodontal treatment. *Journal Indiana Dental Association* 2002; 81 (2): 10-14.

22. Keltjens HMAM, Van Der Hoeven JS, Hendriks JCM. Effects of chlorhexidine gel on periodontal health of abutment teeth in patients with overdentures. Clin Oral Impl Res 1991; 2: 71-74.
23. Keltjens HMAM, Creugers TJ, Schaeken MJM, Van Der Hoeven JS. Effects of chlorhexidine-containing gel and varnish on abutment teeth in patients with overdentures. J Dental Res 1992; 71 (9): 1582-1586.
24. Porras R, Anderson GB, Cafesse R, Narendran S, Trejo PM. Clinical Response to 2 Different Therapeutic Regimens to Treat Peri-Implant Mucositis. J Periodontol 2002; 73 (10): 1118-1125.
25. Pai MR, Acharya LD, Udupa N. The effect of two different dental gels and mouthwash on plaque and gingival scores: a six-week clinical study. Int Dental Journal 2004; 54: 219-223.
26. Hendrikx MJ, Kramer JE, De Baat C. Overdentures covering natural roots. The use of chlorhexidine gel. Ned Tijdschr Tandheelkd 2000; 107 (3): 94-96.
27. Maló P. Carga inmediata en pacientes con maxilar superior totalmente edéntulo. In: Jimenez-López V, eds. Carga o Función Inmediata en Implantología. Aspectos quirúrgicos, protéticos, oclusales y de laboratorio. Barcelona, España: Editorial Quintessence, SL, 2004: 187-221.

28. Pontoriero R, Tonelli MP, Carnecale G, Mombelli A, Nyman SR, Lang NP. Experimentally induced peri-implant mucositis. A clinical study in humans. Clin Oral Impl Res 1994; 5: 254-259.
29. Felo A, Shibly O, Ciancio SG, Lauciello FR, Ho A. Effects of subgingival chlorhexidine irrigation on peri-implant maintenance. Am J Dent 1997; 10 (2): 107-110.
30. Lang NP, Hase JC, Grassi M, et al. Plaque formation and gingivitis after supervised mouthrinsing with 0.2% delmopinol hydrochloride, 0.2% chlorhexidine digluconate and placebo for 6 months. Oral Dis 1998; 4 (2): 105-113.
31. Pirnazar P, Wolinsky L, Nachnani S, Haake S, Pilloni A, Bernard GW. Bacteriostatic effects of hyaluronic acid. J Periodontol 1999; 70 (4): 370-374.
32. Vaahtoniemi LH, Raisanen S, Stenfors LE. Effect of chlorhexidine and toothbrushing on the presence of bacteria on gingival and buccal epithelial cells. Oral Microbiol Imm 1994; 9 (5): 315-317.
33. Hase JC, Edwardsson S, Rundegren J, Attstrom R, Kelty E. 6-month use of 0.2% delmopinol hydrochloride in comparison with 0.2% chlorhexidine digluconate and placebo. J Clin Perio 1998; 25: 841-849.

34. Vianna ME, Gomes BP, Berber VB, Zaia AA, Ferraz CC, Souza-Filho FJ. In vitro evaluation of the antimicrobial activity of chlorhexidine and sodium hypochlorite. Oral Surg Oral Med Oral Pat 2004; 97 (1): 79-84.

35. Boisnic S, Ben Slama L, Branchet-Gumila MC, D'Arros G. Contribution of parodium gel in an experimental model of human gingival inflammation. Rev Stomatol Chir Maxillofac 2003; 104 (4): 201-5.

36. Moseley R, Waddington RJ, Embery G. Hyaluronan and its potential role in periodontal healing. Dental Update 2002; 29 (3): 144-148.

37. Bretz WA, Valente MI, Djahjah C, do Valle EV, Weyant RJ, Nor JE. Chlorhexidine varnishes prevent gingivitis in adolescents. ASDC J Den. Child 2000; 67 (6): 399-402.

Uncorrected version

TABLES INDEX

Table 1: Clinical chronology regarding professional procedure, diagnosis methods and patient procedures in the study

Professional procedures	Study information; Written informed consent 	Oral Hygiene clinical appointment; Oral hygiene instructions; Surgery 	Suture removal; Oral hygiene clinical appointment; Oral hygiene instructions; New toothbrush 	Oral hygiene clinical appointment; Oral hygiene instructions; 	Oral hygiene clinical appointment; Oral hygiene instructions; 	Final diagnosis
Diagnosis methods	 	 	mPII; Sup; mBI; Mob 	mPII; Sup; mBI; Mob; PPD 	mPII; Sup; mBI; Mob; PPD; Periapical X-ray 	mPII; Sup; mBI; Mob; PPD
Time elapsed	Day -1-----	Day 0-----	Day 10-----	Month 2-----	Month 4-----	Month 6
Patient's procedures		Day of the surgery; Beginning of gel therapy	Gel therapy with HA or CHX	Gel therapy with HA or CHX	Gel therapy with HA or CHX	Gel therapy with HA or CHX

Table 2: Clinical and radiological evaluation parameters for the 2 groups

	Group HA			Group CHX			Statistical test	p value
	Mean	SD	Median	Mean	SD	Median		
mPII 1	1.38	0.73	1.75	1.45	0.88	1.5	Kruskal-Wallis	0.597
mBI 1	0.27	0.36	0.25	0.52	0.53	0.50	Kruskal-Wallis	0.131
Mob	No	--	--	No	--	--	N/A	N/A
Sup	No	--	--	No	--	--	N/A	N/A
mPII 2	1.03	0.71	1	1.6	0.55	1.75	Kruskal-Wallis	0.061
mBI 2	0.10	0.13	0	0.37	0.23	0.25	Kruskal-Wallis	0.003*
PPD 1	1.7	0.62	2	1.8	0.56	2	Kruskal-Wallis	0.502
Mob	No	--	--	No	--	--	N/A	N/A
Sup	No	--	--	No	--	--	N/A	N/A
mPII 3	1.4	0.66	1.5	1.42	0.52	1.5	Kruskal-Wallis	0.966
mBI 3	0.18	0.20	0.25	0.23	0.28	0.25	Kruskal-Wallis	0.612
PPD 2	1.6	0.63	2	1.7	0.68	2	Kruskal-Wallis	0.638
Mob	No	--	--	No	--	--	N/A	N/A
Sup	No	--	--	No	--	--	N/A	N/A
x-ray	No	--	--	No	--	--	N/A	N/A
mPII 4	0.93	1.03	1	1.4	0.63	1	Kruskal-Wallis	0.071
mBI 4	1.07	0.70	1	0.87	0.64	1	Kruskal-Wallis	0.417
PPD 3	1.6	0.72	2	1.7	0.64	2	Kruskal-Wallis	0.625
Mob	No	--	--	No	--	--	N/A	N/A
Sup	No	--	--	No	--	--	N/A	N/A

* = statistically significant;
 N/A=not accessed due to all implants had no mobility (Mob), no suppuration (Sup) and no radiolucency around the implant visible in x-ray (x-ray).

Table 3: Modified bleeding index in the second observation for the 2 groups.
 Comparative evaluation at implant level: tilted implant of the 3rd quadrant; axial implant of the 3rd quadrant; tilted implant on the 4th quadrant; axial implant on the 4th quadrant.

	Group HA			Group CHX			Statistical test	p value
	Mean	SD	Median	Mean	SD	Median		
mBI tilted 3 rd quadrant	0.07	0.26	0	0.27	0.59	0	Kruskal-Wallis	0.276
mBI axial 3 rd quadrant	0.13	0.35	0	0.53	0.52	1	Kruskal-Wallis	0.05*
mBI tilted 4 th quadrant	0	0	0	0.27	0.46	0	Kruskal-Wallis	0.369
mBI axial 4 th quadrant	0.20	0.41	0	0.47	0.52	0	Kruskal-Wallis	0.05*

*** = statistically significant**

Uncorrected version

FIGURE LEGEND

Figure 1




Figure 1: Correlation coefficient between the modified plaque index (mPII) and modified bleeding index (mBI). Note the inverse relation between hyaluronic acid and chlorhexidine groups.